Press Releases

 
Press Releases
Date Title and Summary View
Nov 25, 2014 PORTLAND, Ore., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will...
Nov 20, 2014 Initial Purchase of $5.0 Million at $2.00 per share, 9% higher than the market close as of November 18, 2014Agreement structure provides Galena control and flexibility to access capital over the long-term to fund the Company's clinical and development programs PORTLAND, Ore., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. ("Galena" or...
Nov 18, 2014 Enrollment completed six months ahead of schedule Phase 1 and early Phase 2 data to be presented at the American Society of Hematology 56th Annual Meeting in December, with top-line data in mid-year 2015 PORTLAND, Ore., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commer...
Nov 13, 2014 PORTLAND, Ore., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will...
Nov 11, 2014 Trial expands the eligible patient population and overall NeuVax clinical trial portfolio Recent patent allowance provides intellectual property protection for NeuVax in combination with Herceptin in any HER2/neu expressing cancer PORTLAND, Ore., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company...
Nov 7, 2014 Preliminary data shows a 31% recurrence rate in the vaccine group compared to 50% in the control group at a median follow up of 13 months, a 38% reduction in relative risk of recurrence GALE-301 plus GM-CSF is well tolerated and elicits a strong in vivo immune response with primarily Grade 1 and Grade 2 toxicities Top-line data to be pres...
Nov 4, 2014 PORTLAND, Ore., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's Phase 1/2 trial of GALE-301, or Folate Bindi...
Nov 3, 2014 Clinical programs advance on multiple fronts, with trial initiation, trial enrollment, data and IP milestones achieved and anticipated Commercial strategy reinforced with product acquisition and upcoming commercial launchAbstral® (fentanyl) sublingual tablet net revenue was $1.6 million in Q3 2014 and $6.1 million to date this year, with reite...
Oct 27, 2014 PORTLAND, Ore., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that the Company will report its third quarter financial results on Monday, Novembe...
Oct 14, 2014 -  Allowed claims will cover the use of NeuVax alone or in combination to prevent recurrence of any breast cancer tumor expressing low-to-intermediate levels of HER2 -  Extends patent coverage to three main markets, U.S., EU and now Japan PORTLAND, Ore., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceut...
Page:
1
... NextLast
= add release to Briefcase